A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

• Status: Completed
• Trial end date: 2017-04-10
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed

• Participant must have diagnosis of cancer that is advanced or metastatic

• Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy

• If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug

• If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding

Exclusion Criteria:

• Participant must not have symptomatic central nervous system malignancy or metastasis

• Participant must not have current hematologic malignancy

• Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C

• Participant must not have a serious cardiac condition